Mesoblast (MSB) is held by 16 ASX ETFs. Over the last 3 months it fell 5.5%: on $10,000, −$553. We explain 2 big moves in that time.
About MSB
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.6b
- Held by16 ETFs
- Big moves2 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +8.8%15 Jul 2026· Operational
Mesoblast shares surged after the company announced it had enrolled 300 patients in its Phase 3 back pain trial, hitting a key milestone, while continuing momentum from a recent strong Ryoncil commercial launch and FDA BLA progress drove sustained buying interest.
- +7.9%10 Jul 2026· Unknown
Mesoblast shares rose sharply, most likely driven by company-specific news or clinical trial developments not captured in available data sources, as the move is too large to be explained by broad market or sector tailwinds alone.
Held by 16 ETFs
Of every $10,000 in each fund, how much is in MSB today.
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$670.67%
- ISOiShares S&P/ASX Small Ordinaries ETF$660.66%
- FAIRBetaShares Australian Sustainability Leaders ETF$460.46%
- VSOVanguard MSCI Australian Small Companies Index ETF$340.34%
- OZXXGlobal X Australia ex Financials & Resources ETF$270.27%
- EX20BetaShares Australian Ex-20 Portfolio Diversifier ETF$190.19%
- GEARBetaShares Geared Australian Equities Complex ETF$160.16%
- VETHVanguard Ethically Conscious Australian Shares ETF$100.10%
- ROYLBetaShares Global Royalties ETF$8.030.08%
- STWSTATE STREET SPDR S&P/ASX 200 ETF$7.900.08%
Why did MSB rise 8.8% on 15 Jul 2026?
Mesoblast
Mesoblast shares surged after the company announced it had enrolled 300 patients in its Phase 3 back pain trial, hitting a key milestone, while continuing momentum from a recent strong Ryoncil commercial launch and FDA BLA progress drove sustained buying interest.
Multiple news articles from July 14 confirm Mesoblast reached the 300-patient enrolment target in its Phase 3 trial, a clinically significant catalyst that preceded the July 15 price move. This milestone compounds earlier positive sentiment from the Ryoncil commercial debut and FDA BLA progress reported around July 12-13, creating a sustained bullish narrative. No formal ASX announcement was captured in Layer 1, and macro/sector signals were weak or contradictory (the ASX Health sector was actually down on the day), pointing squarely to company-specific news as the driver.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
Sector / macro signals
What it did to the 16 ETFs holding MSB
On $10,000 in each fund, at the weight it holds today
- SSO0.67% of the fund+$6
- ISO0.66% of the fund+$6
- FAIR0.46% of the fund+$4
- VSO0.34% of the fund+$3
- OZXX0.27% of the fund+$2
- EX200.19% of the fund+$2
- GEAR0.16% of the fund+$1
- VETH0.10% of the fund+$1
- ROYL0.08% of the fund+$1
- STW0.08% of the fund+$1
The 10 that hold it most. All 16 are listed on the page under Held by.